Compound Monograph — PX-BPC

BPC-157

Pentadecapeptide — gastric-derived body protection compound

For laboratory research use only. Not for human or veterinary use.

Compound data

Compound class
Pentadecapeptide — synthetic gastric protein fragment
Structure
15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)
Molecular formula
C62H98N16O22
Molar mass
≈ 1,419.5 g/mol
CAS number
137525-51-0
Presentation
Lyophilized powder — 5mg and 10mg vials
Purity specification
≥ 99% by HPLC, identity confirmed by LC-MS
Distinguishing property
Stable in human gastric juice in published stability work

Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein sequence first isolated from human gastric juice. Its 15-amino-acid sequence does not occur as an isolated fragment in nature; it is produced synthetically for research purposes.

BPC-157 is among the most cited peptides in the preclinical literature, with published animal-model research spanning gastrointestinal, musculoskeletal, vascular, and nervous-system endpoints. A frequently noted property in the literature is its unusual stability in gastric juice relative to most peptides.

Mechanism in the research literature

Angiogenesis and growth-factor pathways

Published preclinical work has examined BPC-157 in the context of angiogenic signaling and growth-factor expression, including interactions with VEGF-pathway and nitric-oxide-system endpoints in animal models.

Nitric oxide system interaction

Multiple published studies describe BPC-157's interaction with the nitric oxide system, including counteraction of both NO-blockade and NO-overload models — a bidirectional pattern discussed across the preclinical literature.

Cytoprotective context

The parent protein's gastric origin frames the cytoprotective research context: published animal studies have examined mucosal, tendon, ligament, and organ-protective endpoints following BPC-157 administration in model systems.

Published research summary

  • Hundreds of published preclinical studies have examined BPC-157 in animal models of tendon, ligament, muscle, and gastrointestinal endpoints.
  • Published stability characterization documents resistance to degradation in human gastric juice — unusual among peptides and central to its research interest.
  • Published work has examined BPC-157 in combination-context research alongside TB-500 (the 'Wolverine' research pairing).
  • Every PX-BPC batch is released against ≥ 99% HPLC purity with LC-MS identity confirmation and a lot-specific Certificate of Analysis.

Handling, reconstitution & storage

Storage (lyophilized)
-20 °C long term; 2–8 °C short term; protect from light
Reconstitution
Bacteriostatic water down the vial wall; swirl gently, never shake
Example ratio
5mg vial + 2.0 mL diluent = 2.5 mg/mL (10 units = 250 mcg)
Stability (reconstituted)
Reference ≈ 28–30 days refrigerated at 2–8 °C with bacteriostatic water
Freeze/thaw
Avoid repeated cycling of reconstituted solutions

Frequently asked questions

Research use only. BPC-157 (PX-BPC) is supplied exclusively as a laboratory research compound. It is not a drug, food, or cosmetic, and it is not intended for human or veterinary administration, diagnostic use, or household use. Statements on this page summarize published scientific literature for reference purposes and do not constitute medical advice or health claims. All PX1 Research batches ship with lot-specific Certificates of Analysis confirming ≥ 99% purity by HPLC and identity by LC-MS.